for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adaptive Biotechnologies Corp

ADPT.O

Latest Trade

40.20USD

Change

1.18(+3.02%)

Volume

2,003,806

Today's Range

38.53

 - 

40.68

52 Week Range

34.11

 - 

55.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
39.02
Open
39.47
Volume
2,003,806
3M AVG Volume
--
Today's High
40.68
Today's Low
38.53
52 Week High
55.12
52 Week Low
34.11
Shares Out (MIL)
124.29
Market Cap (MIL)
4,849.72
Forward P/E
-20.33
Dividend (Yield %)
--

Latest Developments

More

Adaptive Biotechnologies Corp Reports Q2 2019 Results

Adaptive Biotechnologies Debut At $39.01, 95% Above IPO Price

Adaptive Biotechnologies Announces Pricing Of IPO At $20.00 Per Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Industry

Biotechnology & Drugs

Contact Info

1551 Eastlake Ave E Ste 200

+1.206.6590067

https://www.adaptivebiotech.com

Executive Leadership

Chad M Robins

President, Chief Executive Officer, Co-Founder

Harlan S. Robins

Co-Founder, Chief Scientific Officer

Dean L. Schorno

Chief Financial Officer

Nancy Louise Hill

Senior Vice President, General Manager - Research Products

.. Willis

Senior Vice President, General Manager - Diagnostic Products

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019(E)

0.1K
EPS (USD)

2019(E)

-1.920
Price To Earnings (TTM)
--
Price To Sales (TTM)
70.10
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.94
LT Debt To Equity (MRQ)
0.94
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up